Inducing multiple antibodies to treat squamous cell esophageal carcinoma
Abstract Background The positive response and the clinical usefulness of 14 serum antibodies in patients with esophageal squamous cell carcinoma (ESCC) were examined in this study. The Cancer Genome Atlas (TCGA) was used to investigate the frequency of gene expressions, mutations, and amplification...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2020-10-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s12885-020-07466-0 |
| _version_ | 1819195167318474752 |
|---|---|
| author | Isamu Hoshino Yoshihiro Nabeya Nobuhiro Takiguchi Hisashi Gunji Fumitaka Ishige Yosuke Iwatate Akiko Kuwajima Fumiaki Shiratori Rei Okada Hideaki Shimada |
| author_facet | Isamu Hoshino Yoshihiro Nabeya Nobuhiro Takiguchi Hisashi Gunji Fumitaka Ishige Yosuke Iwatate Akiko Kuwajima Fumiaki Shiratori Rei Okada Hideaki Shimada |
| author_sort | Isamu Hoshino |
| collection | DOAJ |
| description | Abstract Background The positive response and the clinical usefulness of 14 serum antibodies in patients with esophageal squamous cell carcinoma (ESCC) were examined in this study. The Cancer Genome Atlas (TCGA) was used to investigate the frequency of gene expressions, mutations, and amplification of these 14 antigens and also the possible effects of antibody induction. Methods Blood serum derived from 85 patients with ESCC was collected and analyzed for the 14 antibodies using ELISA. The prognosis between positive and negative antibodies were then compared. The antibody panel included LGALS1, HCA25a, HCC-22-5, and HSP70. Results Patient serum was positive for all antibodies, except VEGF, with the positive rates ranging from 1.18 to 10.59%. Positive rates for LGALS1, HCA25a, HCC-22-5, and HSP70 were > 10%. TCGA data revealed that all antigen-related genes had little or no mutation or amplification, and hence an increase in gene expression affected antibody induction. The positive results from the panel accounted for the positive rate comparable to the combination of CEA and SCC. No significant association was observed between the presence of antibodies and disease prognosis. Conclusions The detection rates of LGALS1, HCA25a, HCC-22-5, and HSP70 were 10% higher in patients with ESCC. Gene overexpression may be involved in such antibody production. These four antibodies were applied as a panel in comparison with conventional tumor markers. Moreover, it was confirmed that the combination of this panel and the conventional tumor markers significantly improved the positive rate. |
| first_indexed | 2024-12-23T02:08:27Z |
| format | Article |
| id | doaj.art-1db9b12533234d58b02e7455b4fe9f9f |
| institution | Directory Open Access Journal |
| issn | 1471-2407 |
| language | English |
| last_indexed | 2024-12-23T02:08:27Z |
| publishDate | 2020-10-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj.art-1db9b12533234d58b02e7455b4fe9f9f2022-12-21T18:03:50ZengBMCBMC Cancer1471-24072020-10-012011910.1186/s12885-020-07466-0Inducing multiple antibodies to treat squamous cell esophageal carcinomaIsamu Hoshino0Yoshihiro Nabeya1Nobuhiro Takiguchi2Hisashi Gunji3Fumitaka Ishige4Yosuke Iwatate5Akiko Kuwajima6Fumiaki Shiratori7Rei Okada8Hideaki Shimada9Division of Gastroenterological Surgery, Chiba Cancer CenterDivision of Gastroenterological Surgery, Chiba Cancer CenterDivision of Gastroenterological Surgery, Chiba Cancer CenterDivision of Gastroenterological Surgery, Chiba Cancer CenterDepartment of Hepatobiliary and Pancreatic Surgery, Chiba Cancer CenterDepartment of Hepatobiliary and Pancreatic Surgery, Chiba Cancer CenterMedical & Biological Laboratories Co., LtdDivision of Gastroenterological Surgery, Chiba Cancer CenterDepartment of Gastroenterological Surgery and Clinical Oncology, Graduate School of Medicine, Toho UniversityDepartment of Gastroenterological Surgery and Clinical Oncology, Graduate School of Medicine, Toho UniversityAbstract Background The positive response and the clinical usefulness of 14 serum antibodies in patients with esophageal squamous cell carcinoma (ESCC) were examined in this study. The Cancer Genome Atlas (TCGA) was used to investigate the frequency of gene expressions, mutations, and amplification of these 14 antigens and also the possible effects of antibody induction. Methods Blood serum derived from 85 patients with ESCC was collected and analyzed for the 14 antibodies using ELISA. The prognosis between positive and negative antibodies were then compared. The antibody panel included LGALS1, HCA25a, HCC-22-5, and HSP70. Results Patient serum was positive for all antibodies, except VEGF, with the positive rates ranging from 1.18 to 10.59%. Positive rates for LGALS1, HCA25a, HCC-22-5, and HSP70 were > 10%. TCGA data revealed that all antigen-related genes had little or no mutation or amplification, and hence an increase in gene expression affected antibody induction. The positive results from the panel accounted for the positive rate comparable to the combination of CEA and SCC. No significant association was observed between the presence of antibodies and disease prognosis. Conclusions The detection rates of LGALS1, HCA25a, HCC-22-5, and HSP70 were 10% higher in patients with ESCC. Gene overexpression may be involved in such antibody production. These four antibodies were applied as a panel in comparison with conventional tumor markers. Moreover, it was confirmed that the combination of this panel and the conventional tumor markers significantly improved the positive rate.http://link.springer.com/article/10.1186/s12885-020-07466-0AutoantibodyEsophageal squamous cell carcinomaTCGA |
| spellingShingle | Isamu Hoshino Yoshihiro Nabeya Nobuhiro Takiguchi Hisashi Gunji Fumitaka Ishige Yosuke Iwatate Akiko Kuwajima Fumiaki Shiratori Rei Okada Hideaki Shimada Inducing multiple antibodies to treat squamous cell esophageal carcinoma BMC Cancer Autoantibody Esophageal squamous cell carcinoma TCGA |
| title | Inducing multiple antibodies to treat squamous cell esophageal carcinoma |
| title_full | Inducing multiple antibodies to treat squamous cell esophageal carcinoma |
| title_fullStr | Inducing multiple antibodies to treat squamous cell esophageal carcinoma |
| title_full_unstemmed | Inducing multiple antibodies to treat squamous cell esophageal carcinoma |
| title_short | Inducing multiple antibodies to treat squamous cell esophageal carcinoma |
| title_sort | inducing multiple antibodies to treat squamous cell esophageal carcinoma |
| topic | Autoantibody Esophageal squamous cell carcinoma TCGA |
| url | http://link.springer.com/article/10.1186/s12885-020-07466-0 |
| work_keys_str_mv | AT isamuhoshino inducingmultipleantibodiestotreatsquamouscellesophagealcarcinoma AT yoshihironabeya inducingmultipleantibodiestotreatsquamouscellesophagealcarcinoma AT nobuhirotakiguchi inducingmultipleantibodiestotreatsquamouscellesophagealcarcinoma AT hisashigunji inducingmultipleantibodiestotreatsquamouscellesophagealcarcinoma AT fumitakaishige inducingmultipleantibodiestotreatsquamouscellesophagealcarcinoma AT yosukeiwatate inducingmultipleantibodiestotreatsquamouscellesophagealcarcinoma AT akikokuwajima inducingmultipleantibodiestotreatsquamouscellesophagealcarcinoma AT fumiakishiratori inducingmultipleantibodiestotreatsquamouscellesophagealcarcinoma AT reiokada inducingmultipleantibodiestotreatsquamouscellesophagealcarcinoma AT hideakishimada inducingmultipleantibodiestotreatsquamouscellesophagealcarcinoma |